title: Bone markers and osteoporosis therapy.
abstract: Several factors are involved in determining bone quality including bone density, bone turnover, the extent of trabecular bone connectivity, cortical porosity and geometry. Metabolically active and in a continuous process of remodeling, approximately 20% of bone tissue is renewed annually. Bone turn over markers (BTM) are frequently used in clinical trials and to provide valid information about the effectiveness of osteoporosis treatment, reflecting the state of bone metabolism and its response to treatment, although they are not useful alone to estimate bone loss. In this review the behavior of BTM from different clinical trials or different osteoporotic drugs will be addressed.
authors.affiliation: Division of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, Brazilian Ministry of Health, University of Pernambuco Medical School, Recife, PE, Brazil.
authors.forename: Francisco
authors.initials: F
authors.lastname: Bandeira
authors.affiliation: Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, United States.
authors.forename: Aline G
authors.initials: AG
authors.lastname: Costa
authors.affiliation: Division of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, Brazilian Ministry of Health, University of Pernambuco Medical School, Recife, PE, Brazil.
authors.forename: Manoel Aderson
authors.initials: MA
authors.lastname: Soares Filho
authors.affiliation: Division of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, Brazilian Ministry of Health, University of Pernambuco Medical School, Recife, PE, Brazil.
authors.forename: Larissa
authors.initials: L
authors.lastname: Pimentel
authors.affiliation: Division of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, Brazilian Ministry of Health, University of Pernambuco Medical School, Recife, PE, Brazil.
authors.forename: Lourena
authors.initials: L
authors.lastname: Lima
authors.affiliation: Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, United States.
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D000469:Alkaline Phosphatase / Q000032:analysis; D015415:Biomarkers / Q000032:analysis*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000502:physiology; D001862:Bone Resorption / Q000188:drug therapy; D001842:Bone and Bones / Q000378:metabolism*; D002986:Clinical Trials as Topic; D024042:Collagen Type I / Q000032:analysis; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D015675:Osteocalcin / Q000032:analysis; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D053244:Osteoprotegerin / Q000032:analysis; D053245:RANK Ligand / Q000032:analysis
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D053244:Osteoprotegerin; D053245:RANK Ligand; D015675:Osteocalcin; D000469:Alkaline Phosphatase